Insider Trends: Checkpoint Therapeutics Insider Disposition Slows 90-Days of Buys
10:48 PM EST, 02/05/2021 (MT Newswires) -- James F Oliviero III, Director and CEO, President and Director, reported a sale of 118,790 shares in Checkpoint Therapeutics (CKPT) on Feb 04, 2021, for $412,270. Oliviero, subsequent to the transactions delineated in the SEC Form 4 filing, has 3,153,210 shares of company stock, which have a market value of $11.2 million as of the prior-day closing price.
In the 90 days prior to the date of this filing, there have been 3 insider transactions reported to the SEC for Checkpoint Therapeutics. These transactions came from the activities of 2 different insiders that resulted in a net acquisition of 687,594 company shares. In the preceding 90-day window of time, there are no insider transactions for the company.
This level of insider transactions is below that of the peer group average in the 207-company Biotechnology & Medical Research peer group over the last 90-day period. Peer group activity averaged 61.7 transactions per company, with company insiders acquiring on average 41,824 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1651407/000110465921013180/xslF345X03/tm215541-2_4seq1.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.